When even the most highly trained surgeons perform procedures on the retina—one of the smallest, most delicate parts of the ...

Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment ... the most common ocular side effects included conjunctival hemorrhage, eye pain ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ... injections (9.6 and 9.4 eye chart letters, respectively). The most ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections ... hemorrhage. Susvimo is also indicated for the treatment of neovascular (wet) age-related macular ...

a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections. The FDA has ...

Eye injections are a treatment, not a cure for this condition, and patients often need frequent injections to maintain their vision. While a diagnosis of macular degeneration can seem scary ...

The safety profile remained consistent with previous studies, with common side effects being cataract and retinal hemorrhage ... are administered by injection into the eye. You should not use ...